Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. (Q46912365)

From Wikidata
Jump to navigation Jump to search
scientific article published in April 2002
edit
Language Label Description Also known as
English
Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.
scientific article published in April 2002

    Statements

    Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study (English)

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit